| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | A synthesized peptide derived from human htrA1 was used as the immunogen for the HTRA1 antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
HTRA1 Antibody / HtrA serine peptidase 1 is a anti-HTRA1 Rabbit antibody Recombinant Rabbit Monoclonal clone 31H06 supplied in Liquid format. Recommended for workflows such as Western blot (WB), Immunocytochemistry (ICC), Immunofluorescence (IF) with listed reactivity in Human.
Key elements and design rationale
- Target: HTRA1
- Antibody details: Rabbit, Recombinant Rabbit Monoclonal, clone 31H06, isotype Rabbit IgG
- Format: Liquid
- Applications (as listed): WB, ICC, IF
Biological background
HtrA serine peptidase 1 has been implicated in cancer, age related macular degeneration, and arthritis. Research with HTRA1 antibody has shown that increased expression suppresses transforming growth factor beta signaling, influencing proliferation and differentiation. In tumors, HTRA1 can act as a tumor suppressor by promoting degradation of pro survival factors, but in other contexts it may enhance invasion by degrading extracellular matrix components. This dual role underscores its complex function in tissue homeostasis and pathology.
In ophthalmology, polymorphisms in the HTRA1 gene are strongly associated with risk of age related macular degeneration. Studies with HTRA1 antibody have demonstrated elevated expression in retinal tissues from affected individuals, suggesting a role in disease pathogenesis through dysregulation of extracellular remodeling and angiogenesis. This makes HtrA serine peptidase 1 an important biomarker and potential therapeutic target in retinal disease.
HTRA1 also contributes to osteoarthritis and inflammatory joint disease. By degrading matrix proteins such as fibronectin and aggrecan, it influences cartilage turnover and inflammation. Research with HTRA1 antibody has confirmed its presence in synovial tissue and joint fluid, where it participates in matrix breakdown. Targeting HTRA1 activity is being investigated as a strategy to slow joint degeneration.
HTRA1 antibody is applied in western blotting, immunohistochemistry, and ELISA. Western blotting reveals multiple processed forms of the protein, immunohistochemistry shows localization in extracellular and pericellular spaces, and ELISA quantifies soluble levels in fluids. These applications make HTRA1 antibody essential in studies of extracellular proteases and disease.
By supplying validated HTRA1 antibody reagents,
Research relevance and current trends
- Connecting protein-level changes to phenotype using orthogonal readouts (genetic perturbation, transcriptomics, imaging).
- Considering isoforms and post-translational regulation when interpreting protein-level changes.
- Comparing results across species and model systems with matched controls.
Common research applications
- Western blotting: compare relative abundance and activation-state changes across conditions.
- Immunofluorescence: visualize subcellular distribution and cell-to-cell heterogeneity.
Interpret changes in signal alongside appropriate controls and, when relevant, in parallel with total-protein or pathway readouts.
Notes for experimental interpretation
- Signal can reflect expression level, isoform composition, and post-translational state; interpret results in the context of your model system and stimuli.
- Species differences and sample matrices can influence epitope recognition; prioritize matched controls and orthogonal confirmation when feasible.
Antibody notes: Monoclonal antibodies provide a defined epitope recognition profile that can support consistent comparisons across experiments.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
